CMS includes Cologuard in updated Medicare Advantage Star Ratings



MADISON, Wis., April 4, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the Centers for Medicare and Medicaid Services (CMS) included Cologuard® in its updated Medicare Advantage Star Ratings program. Medicare Advantage plans now can help increase their Star Ratings when their beneficiaries complete Cologuard, Exact Sciences' non-invasive colon cancer screening test. 
Read More

Exact Sciences and Mayo Clinic study shows promise of new blood-based lung cancer test

AACR abstract highlights methylation markers capable of detecting all types of lung cancer with more than 90% sensitivity and specificity

MADISON, Wis., March 1, 2017 /PRNewswire/ -- A study from Exact Sciences Corp. (Nasdaq: EXAS) and Mayo Clinic released today by the American Association of Cancer Research (AACR) shows promise for the development of a blood-based lung cancer test. Researchers conducted a multi-round study of nearly 400 patients, which demonstrated high accuracy for detecting lung cancer at all stages.

Read More

Exact Sciences generated $99.4 million in revenues during 2016, a 152-percent increase


Cologuard gross margin reached 61 percent in fourth quarter

MADISON, Wis., Feb. 21, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $99.4 million and completed approximately 244,000 Cologuard tests during the year ended Dec. 31, 2016. Full-year 2016 revenues and Cologuard test volume grew 152 percent and 135 percent from 2015, respectively.

Read More

CMS Proposes Inclusion of Cologuard in Medicare Advantage Star Ratings


Cologuard offers health plans an opportunity to increase screening & improve quality ratings

MADISON, Wis., Feb. 2, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Cologuard® is included in the Medicare Advantage Advance Notice and Draft Call letter.  Cologuard's inclusion in the final Star Ratings will allow Medicare Advantage plans to increase their Star Rating when patients complete Exact Sciences' non-invasive colon cancer screening test.

Read More

Exact Sciences to report $99 million in revenues, 150 percent growth for 2016

- Preliminary revenues between $99.0 million and $99.5 million for 2016, a year-over-year increase of 150 percent;
- 244,000 Cologuard tests completed in 2016, a year-over-year increase of 134 percent;
- 9,500 additional providers ordered Cologuard during the fourth quarter, and insurance coverage expanded by 67 percent during 2016. 

MADISON, Wis., Jan. 8, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced today that the company expects to report revenues between $34.9 million and $35.4 million for the fourth quarter ended Dec. 31, 2016, an increase of 142 percent from the same quarter of 2015. The company completed approximately 82,000 Cologuard tests during the fourth quarter of 2016, which represents growth of 114 percent from the same period of 2015. 

Read More

Cologuard Earns Positive Review from Blue Cross Blue Shield Association

MADISON, Wis., Jan. 5, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the Blue Cross Blue Shield Association's (BCBSA) Center for Clinical Effectiveness "Evidence Street" recently released a positive review of Cologuard to its members.  BCBSA is a national federation of 36 Blue Cross and Blue Shield companies that insure one in three Americans. This continues the positive momentum for Cologuard, as coverage increased by 67 percent in 2016 and nearly 163 million Americans are now in health plans that cover the non-invasive colorectal cancer screening option.

Read More

Exact Sciences Joins Deloitte’s Technology Fast 500 as One of the Sector’s Fastest Growing Companies

Exact Sciences Corp. (Nasdaq: EXAS) has earned a place in Deloitte’s Technology Fast 500. The annual list ranks the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors. Exact Sciences ranked 110th on the list with 852-percent revenue growth from 2012 to 2015, the measurement period for the list. The median revenue growth of companies on the list was 290 percent.

Read More

Cologuard Available to Humana Members as In-Network Colon Cancer Screening Option

MADISON, Wis. , Dec. 12, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced today that under a recently-signed contract, Humana Inc. agreed to cover Cologuard as an in-network service for its members, effective January 1, 2017 . Under terms of the agreement, Cologuard will be available to most Humana beneficiaries with no co-pay. Humana covers nearly 10 million beneficiaries and is the nation's fifth largest commercial insurer. 

Read More

Exact Sciences Appoints Jeff Elliott Chief Financial Officer

Respected diagnostics industry expert will help lead efforts to capitalize on market opportunity for Cologuard

MADISON, Wis., Nov. 8, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced the appointment of Jeff Elliott as chief financial officer.  Mr. Elliott, a former senior research analyst at Robert W. Baird & Co., joined Exact Sciences as vice president, business development and strategy, in June 2016 and will begin his new role effective immediately.  

Read More

Exact Sciences' Cologuard Wins Prestigious Prix Galien Award for Best Medical Technology Product

MADISON, Wis., Oct. 28, 2016 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that Cologuard, the first and only FDA-approved noninvasive, stool DNA-based colorectal cancer screening test, has won the 2016 10th Annual Prix Galien USA Award for best medical technology product. Awarded by the Galien Foundation, the Prix Galien USA awards are among the nation's highest honors recognizing biomedical and technology product achievement associated with improving the human condition.

Read More